Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 21;12(11):e063504.
doi: 10.1136/bmjopen-2022-063504.

Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study

Roxane Dumont  1 , Mayssam Nehme  2 , Elsa Lorthe  1 , Carlos De Mestral  1 , Viviane Richard  1 , Helene Baysson  1   3 , Francesco Pennacchio  1 , Julien Lamour  1 , Claire Semaani  1 , María-Eugenia Zaballa  1 , Nick Pullen  1 , Anne Perrin  4 , Arnaud G L'Huillier  4 , Klara Maria Posfay-Barbe  4 , Idris Guessous #  2   3 , Silvia Stringhini #  5   3   6 ; Specchio-COVID19 study group
Collaborators, Affiliations

Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study

Roxane Dumont et al. BMJ Open. .

Abstract

Objectives: To estimate the prevalence of children and adolescents reporting persistent symptoms after SARS-CoV-2 infection.

Design: A random sample of children and adolescents participated with their family members to a serological survey including a blood drawing for detecting antibodies targeting the SARS-CoV-2 nucleocapsid (N) protein and a questionnaire on COVID-19-related symptoms experienced since the beginning of the pandemic.

Setting: The study took place in the canton of Geneva, Switzerland, between June and July 2021.

Participant: 660 children aged between 2 and 17 years old.

Primary and secondary outcome: The primary outcome was the persistence of symptoms beyond 4 weeks comparing seropositive and seronegative participants. The type of declared symptoms were also studied as well as associated risk factors.

Results: Among seropositive children, the sex-adjusted and age-adjusted prevalence of symptoms lasting longer than 2 weeks was 18.3%, compared with 11.1% among seronegatives (adjusted prevalence difference (ΔaPrev)=7.2%, 95% CI: 1.5% to 13.0%). Among adolescents aged 12-17 years, we estimated the prevalence of experiencing symptoms lasting over 4 weeks to be 4.4% (ΔaPrev,95% CI: -3.8% to 13.6%), whereas no seropositive child aged 2-11 reported symptoms of this duration. The most frequently declared symptoms were fatigue, headache and loss of smell.

Conclusions: We estimated the prevalence of experiencing persistent symptoms lasting over 4 weeks to be around 4% among adolescents, which represents a large absolute number, and should raise awareness and concern. We did not observe meaningful differences of persistent symptoms between seropositive and seronegative younger children, suggesting that they may be less affected than their older counterparts.

Keywords: epidemiology; paediatric infectious disease & immunisation; public health.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Age-adjusted and sex-adjusted prevalence and prevalence difference of persistent symptoms’ duration, stratified by age group and serological status.
See this image and copyright information in PMC

References

    1. Shah W, Hillman T, Playford ED, et al. Managing the long term effects of covid-19: summary of NICE, sign, and RCGP rapid guideline. BMJ 2021;372:n136. 10.1136/bmj.n136 - DOI - PubMed
    1. The Lancet . Facing up to long COVID. Lancet 2020;396:396. 10.1016/S0140-6736(20)32662-3 - DOI - PMC - PubMed
    1. Diaz JV, Soriano JB. A Delphi consensus to advance on a clinical case definition for post COVID-19 condition: a who protocol 2021. - PMC - PubMed
    1. Mahase E. Covid-19: What do we know about "long covid"? BMJ 2020;370:m2815. 10.1136/bmj.m2815 - DOI - PubMed
    1. Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021;4:e210830. 10.1001/jamanetworkopen.2021.0830 - DOI - PMC - PubMed

Publication types

LinkOut - more resources